The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Are CAR NK-cells the future of CLL therapy?
CAR T-cells have the potential to revolutionize tthe reatment of multiple hematological malignancies; however, they do not come without setbacks, as William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, explains. Therapies must be individually cultivated, which is time consuming and therefore dangerous in an aggressive disease, and the toxicities associated with CAR T-cells are considerable. Prof. Wierda discusses an alternative: CAR NK-cells. CAR NK-cell therapy appears, from early clinical trial data, to be highly effective and importantly, more tolerable than CAR T-cell therapy. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.
